Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061175 | 0.90 | HSD11B1 (0.43) | EPHX1POLBHSD11B1DRD2GNAI3 | |
| SCHEMBL14919674 | 0.88 | DRD2 (0.50) | EPHX1HSD11B1DRD2HTR1AHTR2A | |
| SCHEMBL9653152 | 0.84 | EPHX1 (0.46) | EPHX1POLBHSD11B1GNAI3GNAO1 | |
| SCHEMBL19086770 | 0.83 | EPHX1 (0.48) | EPHX1POLBHSD11B1GNAI3GNAO1 | |
| SCHEMBL15226075 | 0.83 | EPHX1 (0.55) | EPHX1HSD11B1SMN1; SMN2EPHX2 | |
| SCHEMBL3835430 | 0.83 | HSD11B1 (0.43) | EPHX1HSD11B1DRD2HTR1AHTR2A | |
| SCHEMBL1693037 | 0.82 | DRD2 (0.50) | EPHX1HSD11B1DRD2HTR1AHTR2A | |
| SCHEMBL966144 | 0.81 | MAPK1 (0.44) | EPHX1HSD11B1DRD2SMN1; SMN2 | |
| SCHEMBL19570445 | 0.81 | HSD11B1 (0.44) | EPHX1POLBHSD11B1DRD2HTR1A | |
| SCHEMBL883979 | 0.81 | EPHX1 (0.53) | EPHX1POLBHSD11B1DRD2GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8329702-B2 | Heterocycles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2496557-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2352734-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110059984-A1 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7880008-B2 | Such as 4-(-1,2,4-thiadiazol-3-yl)piperazine-1-carboxylate and 4-(thiazol-2-yl)piperazine-1-carboxylate derivatives; antiinflammatory, anticarcinogenic, antiepileptic, antiarthritic, and analgesic agents; neurodegenerative and muscular disorders; sodium and calcium channel modulators; diabetes, headaches | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| EP-1583537-A3 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1583537-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197333-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS PHARMA LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005062882-A2 | RIFAMYCIN ANALOGS AND USES THEREOF | ACTIVBIOTICS, INC (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005020894-A2 | RIFAMYCIN ANALOGS AND USES THEREOF | ACTIVBIOTICS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043298-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS PHARMA LLC | 2005-02-24 | — | — | US | disclosed |
| WO-2004087145-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004002490-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
| EP-0467325-A2 | Carbostyril derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5082847-A | Antiarrhythmia | SYNTEX (U.S.A.) INC. (US) | 1992-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197333-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | EPHX1 2641/4885POLB 1001/4885HSD11B1 1138/4885 |
| US-20050043298-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | EPHX1 2641/4885POLB 1001/4885HSD11B1 1138/4885 |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | EPHX1 826/4885POLB 1108/4885HSD11B1 1919/4885 |
| US-20110059984-A1 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | EPHX1 1288/4885POLB 4597/4885HSD11B1 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.